09:47 AM EDT, 08/12/2026 (MT Newswires) -- Monopar Therapeutics ( MNPR ) reported a Q2 net loss Wednesday of $0.62 per diluted share, compared with a loss of $0.35 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.66.

The company did not report any revenue for the quarter.

As of June 30, the company said it has $134.3 million in cash, cash equivalent and investments. It added that it expects its current funds to support operations through at least Dec. 31, 2027.

Price: 115.00, Change: +0.54, Percent Change: +0.47